Printer Friendly

Eisai Introduces Rx-to-OTC Switch Product for Allergy-related Rhinitis and Skin Problems.

Tokyo, Japan, Oct 31, 2006 - (JCN) - Eisai has introduced a Rx-to-OTC switch product for allergic-related rhinitis and skin problems, available from November 1.

The product, 'Higuard', is the first Rx-to-OTC switch product of azelastine hydrochloride, an anti-allergy compound originally approved for prescription use. It is also effective in alleviating allergyc symptoms including rhinitis caused by pollens or house dusts and skin problems such as utricaria and eczema.

The active ingredient of Higuard azelastine hydrochloride exhibits anti-allergic effects by inhibiting and releasing leukotriens and histamine that cause allergy, relieving allergic symptoms including rhinitis (sneezing, runny and stuffy nose) and skin problems (urticaria, eczema, etc).

It is recommended that patients with seasonal allergic diseases be started on Higuard immediately before the beginning of the season to maximize the effect.

According to an Eisai survey, more than 50 percent of the people who suffer from pollen allergy answered that they constantly feel itching of skin, and 70 percent said that they experience allergic problems all year. Higuard is expected to serve the needs of such people acting on both rhinitis and skin problems.

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.
COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2006, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:JCNN News Summaries
Date:Oct 31, 2006
Previous Article:Marubeni, Seimens Win 37 Bln Order for Combined Cycle Power Plant in Thailand.
Next Article:Advantest Showcases Total Test Solutions at Semicon Japan 2006.

Related Articles
The importance of quantifying skin reactivity in treating allergic rhinitis with immunotherapy.
The treatment of allergic rhinitis with immunotherapy: A review of 1,000 cases.
Allergies & women's health.
Nasopharyngeal carcinoma and nasal allergy: any correlation? (Original Article).
Comparison of intranasal hypertonic Dead Sea saline spray and intranasal aqueous triamcinolone spray in seasonal allergic rhinitis.
The shape of food allergenicity.
Fungal levels in the home and allergic rhinitis by 5 years of age.
Effects in infants from tobacco smoke, mold, and older siblings.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters